Ascendis Pharma A/S (ASND) News Today $129.81 +7.17 (+5.85%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Valence8 US LP Invests $685,000 in Ascendis Pharma A/S (NASDAQ:ASND)Valence8 US LP purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,585 shares of the biotechnology company's stock, valueNovember 22 at 8:01 AM | marketbeat.comCan BioMarin Stock Live Up to Wall Street’s High Expectations? (ASND)BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?November 22 at 7:00 AM | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and twelve have assigned aNovember 20 at 3:50 AM | marketbeat.comStockNews.com Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to HoldStockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday.November 20 at 3:17 AM | marketbeat.comAscendis Pharma: Strategic Expansion and Product Launches Drive Future Growth, Outperform Rating ReaffirmedNovember 19, 2024 | markets.businessinsider.comFirst Turn Management LLC Trims Position in Ascendis Pharma A/S (NASDAQ:ASND)First Turn Management LLC reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 19.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 150,593 shares of the biotechnology company's stock after selling 35,988 shares duNovember 19, 2024 | marketbeat.comTD Cowen Has Lowered Expectations for Ascendis Pharma A/S (NASDAQ:ASND) Stock PriceNovember 19, 2024 | americanbankingnews.comWedbush Reiterates Outperform Rating for Ascendis Pharma A/S (NASDAQ:ASND)November 19, 2024 | americanbankingnews.comStifel Nicolaus Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) StockNovember 18, 2024 | americanbankingnews.comOppenheimer Cuts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $180.00November 18, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Sees Large Growth in Short InterestAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 3,410,000 shares, a growth of 5.6% from the October 15th total of 3,230,000 shares. Based on an average daily volume of 634,100 shares, the short-interest ratio is currently 5.4 days.November 17, 2024 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Ascendis Pharma A/S (NASDAQ:ASND)November 17, 2024 | americanbankingnews.comAscendis Pharma price target lowered to $153 from $160 at TD CowenNovember 15, 2024 | markets.businessinsider.comTD Cowen Cuts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $153.00TD Cowen reduced their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research note on Friday.November 15, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Down on Analyst DowngradeAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Down Following Analyst DowngradeNovember 15, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $180.00 at OppenheimerOppenheimer lowered their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research report on Friday.November 15, 2024 | marketbeat.comAscendis Pharma Reports Strong Q3 2024 ResultsNovember 15, 2024 | markets.businessinsider.comAscendis Pharma’s Strategic Advances and Yorvipath Launch Position Stock for Growth: Buy Rating Affirmed by AnalystNovember 15, 2024 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday.November 15, 2024 | marketbeat.comStifel Nicolaus Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock PriceStifel Nicolaus lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research report on Friday.November 15, 2024 | marketbeat.comAscendis Pharma A/S's (ASND) "Outperform" Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday.November 15, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Rating Lowered to "Sell" at StockNews.comNovember 15, 2024 | americanbankingnews.comAscendis Pharma A/S (ASND) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comAscendis Pharma Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comSivik Global Healthcare LLC Buys Shares of 10,000 Ascendis Pharma A/S (NASDAQ:ASND)Sivik Global Healthcare LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,000 shares of the biotechnology company's stock, valued at approximately $1,493,000. A numbNovember 14, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 69.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,403 shares of the biotechnology comNovember 14, 2024 | marketbeat.comCrossmark Global Holdings Inc. Takes $1.21 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)Crossmark Global Holdings Inc. bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,120 shares of the biotechnology company's sNovember 14, 2024 | marketbeat.comAscendis Pharma Expands Capital to Fuel GrowthNovember 13, 2024 | markets.businessinsider.comTimesSquare Capital Management LLC Decreases Holdings in Ascendis Pharma A/S (NASDAQ:ASND)TimesSquare Capital Management LLC lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 16.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 500,920 sNovember 10, 2024 | marketbeat.comAscendis Pharma A/S (ASND) Set to Announce Quarterly Earnings on ThursdayAscendis Pharma A/S (NASDAQ:ASND) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports.November 8, 2024 | marketbeat.comJackson Square Capital LLC Buys Shares of 9,651 Ascendis Pharma A/S (NASDAQ:ASND)Jackson Square Capital LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,651 shares of the biotechnology company's stock, valued at approxiNovember 7, 2024 | marketbeat.comAnalysts Offer Predictions for ASND Q3 EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Investment analysts at Wedbush issued their Q3 2024 earnings per share (EPS) estimates for Ascendis Pharma A/S in a report issued on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the biotechnology company will earn ($1.98) per shNovember 7, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Raised to Strong-Buy at WedbushWedbush upgraded shares of Ascendis Pharma A/S to a "strong-buy" rating in a research note on Monday.November 6, 2024 | marketbeat.comAscendis Pharma’s Strategic Partnership with Novo Nordisk: A Promising Buy Opportunity Fueled by TransCon TechnologyNovember 5, 2024 | markets.businessinsider.comAscendis Pharma’s Strategic Partnership with Novo Nordisk Signals Strong Buy Rating Amid Growing Obesity MarketNovember 5, 2024 | markets.businessinsider.comWegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity DrugNovember 4, 2024 | finance.yahoo.comAscendis Pharma (ASND) Receives a Buy from Cantor FitzgeraldNovember 4, 2024 | markets.businessinsider.comAscendis Pharma A/S's (ASND) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday.November 4, 2024 | marketbeat.comNew York State Common Retirement Fund Has $26.77 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)New York State Common Retirement Fund trimmed its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 10.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 179,318 shares of the biotechnology company's stock afNovember 4, 2024 | marketbeat.comHarbor Capital Advisors Inc. Increases Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Harbor Capital Advisors Inc. lifted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 67.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 87,302 shares of the biotechnology company's stock after purchasing an additional 35,102 shareNovember 3, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Position Raised by Rice Hall James & Associates LLCRice Hall James & Associates LLC raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 160,614 shares of the biotechnology company's stockNovember 1, 2024 | marketbeat.comChina Universal Asset Management Co. Ltd. Buys 4,338 Shares of Ascendis Pharma A/S (NASDAQ:ASND)China Universal Asset Management Co. Ltd. grew its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 63.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,142 shares of the biotecOctober 29, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Sells 17,842 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Allspring Global Investments Holdings LLC trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 10.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 161,410 shares of the biotechnology company's stock after selling 1October 24, 2024 | marketbeat.comAscendis Pharma’s Growth Prospects Bolstered by Yorvipath Launch and Strategic InitiativesOctober 23, 2024 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Given New $174.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. decreased their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a research report on Wednesday.October 23, 2024 | marketbeat.comAscendis Pharma price target raised to $160 from $157 at TD CowenOctober 22, 2024 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) PT Raised to $160.00TD Cowen boosted their price target on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a "buy" rating in a research report on Monday.October 21, 2024 | marketbeat.comAscendis Pharma (ASND) Receives a Hold from Morgan StanleyOctober 14, 2024 | markets.businessinsider.comHandelsbanken Fonder AB Has $2.64 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Handelsbanken Fonder AB raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 31.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,667 shares of theOctober 10, 2024 | marketbeat.comMorgan Stanley Sticks to Their Hold Rating for Ascendis Pharma (ASND)October 8, 2024 | markets.businessinsider.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.320.49▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼136▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News Today TEVA News Today BGNE News Today VTRS News Today MRNA News Today SMMT News Today GMAB News Today RDY News Today PCVX News Today CTLT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
